Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_875861f3a625de7c6408a9b49f0b680d |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4035 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107 |
filingDate |
2016-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2902c2de2c4756eb78707de56ce82a0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_358ecbb7a51fada0d33e764d5f897914 |
publicationDate |
2017-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2017135923-A1 |
titleOfInvention |
Emulsion comprising an nk-1 receptor antagonist |
abstract |
Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11065265-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019152430-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109453115-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108703950-A |
priorityDate |
2016-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |